Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Next Previous
X
Search
Trial Profile

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Denosumab; Dexamethasone; Gallium (68Ga) gozetotide; Zoledronic acid
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VISION
  • Sponsors Endocyte

    • Most Recent Events

    • 01 Aug 2024 Results of sub study assessing dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer published in the Radiology.
    • 01 Apr 2024 Results evaluating the safety of additional cycles of 177Lu-PSMA-617 and the impact of longer observation time for patients receiving 177Lu-PSMA-617 plus SoC published in the European Urology
    • 10 Jan 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top